MUMBAI: Indian drug makers have already become a formidable force in bringing out generic forms of chemically-synthesised medicines, especially in the US market, and now are gearing up to break into the follow-on biologics segment. As biotechnology products go off patent, generic drug makers will make similar copies of those drugs and bring them to market at a fraction of the cost of the innovator drug. This ‘biosimilar’ drug market promises to be more profitable than the chemical generics market.
